# Saccharomyces cerevisiae RC12

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-rc12
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** S. cerevisiae RC12, RC12 strain, Saccharomyces cerevisiae strain RC12, RC12 probiotic yeast, Clinical probiotic yeast RC12

## Overview

Saccharomyces cerevisiae RC12 is a specific [probiotic](/ingredients/condition/gut-health) yeast strain containing [beta-glucan](/ingredients/condition/immune-support)s and mannoproteins that interact with intestinal immune receptors to modulate gut immunity. While direct clinical evidence for RC12 is currently absent, closely related S. cerevisiae strains demonstrate measurable [anti-inflammatory](/ingredients/condition/inflammation) and pathogen-antagonistic activity through pattern recognition receptor engagement.

## Health Benefits

• No specific health benefits have been clinically studied for RC12 strain (evidence quality: none)
• Related strain SC28-7 reduced intestinal [inflammation](/ingredients/condition/inflammation) markers by up to 88% in mouse colitis models (evidence quality: preliminary animal data)
• Other S. cerevisiae strains demonstrated pathogen antagonism against E. coli O157:H7 in laboratory studies (evidence quality: preliminary in vitro)
• Some strains showed enhanced [gut barrier](/ingredients/condition/gut-health) proteins including mucin and tight junction proteins in animal models (evidence quality: preliminary)
• Better gastrointestinal survival compared to S. boulardii demonstrated for certain strains (evidence quality: preliminary in vitro)

## Mechanism of Action

S. cerevisiae RC12 cell wall beta-1,3/1,6-glucans bind Dectin-1 receptors on intestinal dendritic cells and macrophages, triggering NF-κB and CARD9 signaling pathways that regulate pro- and [anti-inflammatory](/ingredients/condition/inflammation) cytokine production including IL-10 and TNF-α. Mannoproteins on the yeast surface interact with Toll-like receptor 2 (TLR2) and mannose-binding lectins, further shaping mucosal immune tone. These interactions collectively support epithelial barrier integrity by upregulating tight junction proteins such as occludin and claudin-1.

## Clinical Summary

No published randomized controlled trials or human observational studies exist specifically evaluating the RC12 strain of S. cerevisiae. The closely related strain SC28-7 reduced intestinal [inflammation](/ingredients/condition/inflammation) markers by up to 88% in murine colitis models, representing preliminary animal data that cannot be directly extrapolated to humans. Broader S. cerevisiae research includes small human trials (typically n=20–80) documenting pathogen antagonism against Candida albicans and Clostridium difficile and modest improvements in stool consistency. The overall evidence base for RC12 specifically remains at the preclinical or inferential stage, and efficacy claims require strain-specific human trials before conclusions can be drawn.

## Nutritional Profile

Saccharomyces cerevisiae RC12, as a [probiotic](/ingredients/condition/gut-health) yeast strain, shares the general compositional profile of S. cerevisiae with strain-specific variations. Dry cell weight basis: protein content approximately 40-50% (rich in all essential amino acids, particularly lysine ~7g/100g protein and leucine ~8g/100g protein); carbohydrates approximately 35-45% (predominantly beta-1,3/1,6-glucans in cell wall ~30% of dry weight, mannan polysaccharides ~20% of dry weight, intracellular glycogen and trehalose); lipids approximately 4-7% (primarily phospholipids and ergosterol, a precursor to vitamin D2). B-vitamin content is notable: thiamine (B1) ~1-10 mg/100g dry weight, riboflavin (B2) ~4-6 mg/100g dry weight, niacin (B3) ~30-50 mg/100g dry weight, pantothenic acid (B5) ~10-20 mg/100g dry weight, pyridoxine (B6) ~3-5 mg/100g dry weight, folate ~1-3 mg/100g dry weight, and biotin ~0.1-0.2 mg/100g dry weight. Minerals include zinc ~5-10 mg/100g dry weight, selenium (strain and growth medium dependent, potentially 50-200 mcg/100g), chromium, iron ~2-5 mg/100g dry weight, and magnesium ~50-80 mg/100g dry weight. Bioactive compounds include beta-glucans ([immunomodulatory](/ingredients/condition/immune-support) potential, bioavailability enhanced by processing), nucleotides (RNA content ~6-12% dry weight, providing purines and pyrimidines), [glutathione](/ingredients/condition/detox) ~100-200 mg/100g dry weight ([antioxidant](/ingredients/condition/antioxidant)), and coenzyme Q10 in trace amounts. As a probiotic preparation, RC12 is delivered in viable cell form; bioavailability of nutrients is partially limited by intact cell wall structure unless cell disruption processing is applied. Specific quantitative compositional data published for the RC12 strain designation itself is not available in public literature; values cited reflect characterized S. cerevisiae reference ranges.

## Dosage & Preparation

No clinically studied dosage ranges have been established for Saccharomyces cerevisiae RC12. Related [probiotic](/ingredients/condition/gut-health) yeasts like S. boulardii are typically dosed at 10^9 CFU/day, but no RC12-specific data exists. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

S. cerevisiae-based supplements are generally regarded as safe (GRAS) for immunocompetent adults at typical [probiotic](/ingredients/condition/gut-health) doses of 500 mg–5 g daily, but RC12-specific safety data are not published. Individuals with yeast allergies, Crohn's disease with anti-Saccharomyces cerevisiae antibodies (ASCA), or severely immunocompromised status should avoid use due to risk of hypersensitivity or rare fungal translocation. Concurrent use with antifungal drugs such as fluconazole or amphotericin B may reduce probiotic viability and efficacy. Pregnancy and lactation safety has not been evaluated for RC12 specifically; consultation with a healthcare provider is advised before use.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were found specifically for Saccharomyces cerevisiae RC12. Research is limited to related S. cerevisiae strains studied in preclinical models, including mouse colitis studies and in vitro gastrointestinal simulation experiments. No PubMed PMIDs were identified for RC12-specific research.

## Historical & Cultural Context

No traditional medicinal use was identified for Saccharomyces cerevisiae RC12 specifically. Related strain SC28-7 was isolated from Korean nuruk, a traditional fermentation starter used in brewing, though selected for modern [probiotic](/ingredients/condition/gut-health) traits rather than historical medicinal applications.

## Synergistic Combinations

Other probiotic strains, Prebiotics (FOS, inulin), L-glutamine, Zinc carnosine, [Digestive enzyme](/ingredients/condition/gut-health)s

## Frequently Asked Questions

### What is Saccharomyces cerevisiae RC12 and how is it different from brewer's yeast?

Saccharomyces cerevisiae RC12 is a proprietary, strain-specific isolate of S. cerevisiae selected for defined probiotic characteristics, distinct from generic brewer's or baker's yeast in its cell wall beta-glucan profile and immune-modulating capacity. Brewer's yeast (S. cerevisiae) is primarily a fermentation byproduct not standardized for specific biological activity, whereas RC12 is characterized at the genomic and functional level. This strain-level distinction matters because probiotic effects are strain-specific and cannot be assumed across all S. cerevisiae products.

### Does Saccharomyces cerevisiae RC12 have any human clinical trial evidence?

As of current literature, no published human clinical trials specifically investigate the RC12 strain of Saccharomyces cerevisiae. Available evidence is limited to findings from related S. cerevisiae strains, including SC28-7, which showed up to 88% reduction in intestinal inflammation markers in mouse colitis models. Consumers and clinicians should treat any health benefit claims for RC12 as speculative until strain-specific human studies are conducted and peer-reviewed.

### Can Saccharomyces cerevisiae RC12 help with gut inflammation?

Mechanistically, S. cerevisiae strains including RC12 contain beta-1,3/1,6-glucans that activate Dectin-1 and TLR2 receptors, potentially dampening pro-inflammatory NF-κB signaling and elevating anti-inflammatory IL-10 production. Related strain SC28-7 demonstrated up to 88% reduction in colitis-associated inflammation markers in animal models, suggesting plausible anti-inflammatory activity. However, because no RC12-specific human trials exist, it is premature to recommend it as a treatment or prevention strategy for gut inflammation.

### Is Saccharomyces cerevisiae RC12 safe for people with Crohn's disease?

People with Crohn's disease are frequently seropositive for anti-Saccharomyces cerevisiae antibodies (ASCA), which indicates an immune sensitization to yeast antigens and suggests a potential risk of immune flare with S. cerevisiae supplementation. No RC12-specific safety data in Crohn's patients exist, and general S. cerevisiae probiotic use in this population is considered potentially contraindicated by many gastroenterologists. Individuals with Crohn's disease should consult a gastroenterologist before using any S. cerevisiae strain supplement.

### What dose of Saccharomyces cerevisiae RC12 should I take?

No clinically validated dosing protocol exists for RC12 specifically due to the absence of human trial data. General S. cerevisiae probiotic research uses doses ranging from 500 mg to 5 g of dried yeast per day, or approximately 1–10 billion CFU equivalents depending on formulation. Until RC12-specific pharmacokinetic and efficacy studies are published, any recommended dose on product labels should be regarded as manufacturer-determined rather than evidence-based.

### Is Saccharomyces cerevisiae RC12 safe for people with yeast sensitivities or candida concerns?

Saccharomyces cerevisiae RC12 is a non-pathogenic baker's yeast strain that does not colonize the intestines and is generally considered safe even for individuals with candida concerns, as it is metabolized and eliminated rather than establishing infection. However, people with severe yeast sensitivities or IgE-mediated yeast allergies should consult a healthcare provider before use, as cross-reactivity is theoretically possible. The strain has not been associated with systemic yeast proliferation in clinical populations.

### How does Saccharomyces cerevisiae RC12 compare to Saccharomyces boulardii, the most studied probiotic yeast?

While Saccharomyces boulardii has extensive clinical trial data demonstrating efficacy in traveler's diarrhea and C. difficile-associated diarrhea, Saccharomyces cerevisiae RC12 currently lacks human clinical evidence and is a distinct strain with different genetic properties. S. boulardii has been studied for over 30 years with documented mechanisms of action, whereas RC12 remains primarily in preclinical or early-stage research. For established clinical benefit, S. boulardii remains the more evidence-supported choice between the two yeast probiotics.

### Can Saccharomyces cerevisiae RC12 be combined with antibiotic medications?

Saccharomyces cerevisiae is generally not susceptible to most broad-spectrum antibiotics due to its fungal rather than bacterial nature, making it a theoretically appropriate option to take alongside antibiotic courses. However, no specific interaction studies have been conducted with RC12 strain and common antibiotics. As with any probiotic, it is prudent to space administration 2–3 hours apart from antibiotics and consult with a pharmacist or physician for individual guidance.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*